Real-life experience with CPX-351 and impact on the outcome of high-risk AML patients: a multicentric French cohort - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue Blood Advances Année : 2021

Real-life experience with CPX-351 and impact on the outcome of high-risk AML patients: a multicentric French cohort

(1, 2) , (3) , (4, 5) , (6) , (7, 8, 9) , (10) , (7, 8) , (11) , (11) , (12) , (2, 13) , (14) , (14, 15) , (15, 14) , (3) , (13) , (16) , (16) , (17) , (17) , (18) , (6) , (10) , (4, 5) , (3, 19) , (13, 2)
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
Pierre-Yves Dumas
Alexis Caulier
  • Fonction : Auteur
  • PersonId : 1151781
  • IdRef : 194466000
Norbert Vey

Résumé

CPX-351 is a liposomal formulation of cytarabine and daunorubicin approved for the treatment of adults with newly diagnosed, therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (MRC-AML). We retrospectively analyzed the efficacy and safety of CPX-351 in a real-world setting in 103 patients from 12 French centers, including the evaluation of molecular abnormalities at baseline and minimal residual disease (MRD) in responding patients, compared with a historical data set from Bordeaux-Toulouse DATAML registry. A favorable safety profile was observed, with a low frequency of alopecia (11%) and gastrointestinal toxicity (50%). The overall response rate after induction was 59%, and MRD,1023 was achieved in 57% of complete response (CR)/CR with incomplete hematological recovery (CRi) patients. Only the presence of mutated TP53 (P = .02) or PTPN11 (P = .004) predicted lower response in multivariate analysis. Interestingly, high-risk molecular prognosis subgroups defined by 2017 European LeukemiaNet risk stratification, including ASXL1 and RUNX1 mutations, were not associated with a significantly lower response rate using CPX-351. With amedian follow-up of 8.6 months, median overall survival (OS) was 16.1 months. Thirty-six patients underwent allogeneic stem cell transplantation with a significantly longer median OS compared with nontransplanted patients (P<.001). In multivariate analyses, only spliceosome mutations were associated with better OS (P=.04). In comparison with intensive chemotherapy, there was no difference in OS for patients,60 years. These data confirm the efficacy and safety of CPX-351 in high-risk AML(t-AML and MRC-AML) in a real-life setting. CPX-351 is a treatment of choice for patients aged >60 years.

Dates et versions

hal-03605963 , version 1 (11-03-2022)

Identifiants

Citer

Edmond Chiche, Ramy Rahme, Sarah Bertoli, Pierre-Yves Dumas, Jean-Baptiste Micol, et al.. Real-life experience with CPX-351 and impact on the outcome of high-risk AML patients: a multicentric French cohort. Blood Advances, 2021, 5 (1), pp.176-184. ⟨10.1182/bloodadvances.2020003159⟩. ⟨hal-03605963⟩
15 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook Twitter LinkedIn More